[go: up one dir, main page]

TN2009000544A1 - Derives de benzimidazole - Google Patents

Derives de benzimidazole

Info

Publication number
TN2009000544A1
TN2009000544A1 TNP2009000544A TN2009000544A TN2009000544A1 TN 2009000544 A1 TN2009000544 A1 TN 2009000544A1 TN P2009000544 A TNP2009000544 A TN P2009000544A TN 2009000544 A TN2009000544 A TN 2009000544A TN 2009000544 A1 TN2009000544 A1 TN 2009000544A1
Authority
TN
Tunisia
Prior art keywords
benzimidazole derivatives
mammals
compounds
treatment
cell growth
Prior art date
Application number
TNP2009000544A
Other languages
English (en)
Inventor
Christopher Scott Jones
GRECA Susan LA
Qifang Li
Michael John Munchhof
Lawrence Alan Reiter
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TN2009000544A1 publication Critical patent/TN2009000544A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un composé de formule (I) ou un de ses sels pharmaceutiquement acceptables, formule dans laquelle R1, R2, R3A, R3B, R4, R5, X, m et n sont tels que définis ici. Ces dérivés de benzamidazole nouveaux sont utiles dans le traitement de la croissance cellulaire anormale, telle qu'un cancer, chez des mammifères. Cette invention concerne également un procédé d'utilisation de ces composés dans le traitement de la croissance cellulaire anormale chez des mammifères, notamment des êtres humains, et des compositions pharmaceutiques contenant ces composés.
TNP2009000544A 2007-06-29 2009-12-25 Derives de benzimidazole TN2009000544A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94728707P 2007-06-29 2007-06-29
US4164508P 2008-04-02 2008-04-02
PCT/IB2008/001575 WO2009004427A2 (fr) 2007-06-29 2008-06-16 Dérivés de benzamidazole

Publications (1)

Publication Number Publication Date
TN2009000544A1 true TN2009000544A1 (fr) 2011-03-31

Family

ID=40161351

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000544A TN2009000544A1 (fr) 2007-06-29 2009-12-25 Derives de benzimidazole

Country Status (45)

Country Link
US (2) US8148401B2 (fr)
EP (1) EP2170860B9 (fr)
JP (2) JP4567099B2 (fr)
KR (1) KR101143246B1 (fr)
CN (1) CN101687841B (fr)
AP (1) AP2377A (fr)
AR (1) AR067346A1 (fr)
AU (1) AU2008272641B2 (fr)
BR (1) BRPI0813412B8 (fr)
CA (1) CA2690953C (fr)
CL (1) CL2008001922A1 (fr)
CO (1) CO6160232A2 (fr)
CR (1) CR11150A (fr)
CU (1) CU23847B1 (fr)
CY (2) CY1118650T1 (fr)
DK (1) DK2170860T5 (fr)
DO (1) DOP2009000278A (fr)
EA (1) EA016888B1 (fr)
EC (1) ECSP099803A (fr)
ES (1) ES2609258T3 (fr)
FR (1) FR20C1038I2 (fr)
GE (1) GEP20125702B (fr)
GT (1) GT200900328A (fr)
HN (1) HN2008000974A (fr)
HR (1) HRP20161562T2 (fr)
HU (2) HUE030052T4 (fr)
IL (1) IL202420A (fr)
LT (2) LT2170860T (fr)
MA (1) MA31466B1 (fr)
ME (1) ME00962B (fr)
MY (1) MY148636A (fr)
NI (1) NI200900219A (fr)
NL (1) NL301057I2 (fr)
NO (1) NO2020027I1 (fr)
NZ (1) NZ581889A (fr)
PA (1) PA8785401A1 (fr)
PE (2) PE20121010A1 (fr)
PL (1) PL2170860T3 (fr)
PT (1) PT2170860T (fr)
RS (1) RS55395B9 (fr)
SI (1) SI2170860T1 (fr)
TN (1) TN2009000544A1 (fr)
TW (1) TWI371451B (fr)
UY (1) UY31164A1 (fr)
WO (1) WO2009004427A2 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ581889A (en) * 2007-06-29 2011-05-27 Pfizer Benzimidazole derivatives
WO2010028192A1 (fr) 2008-09-03 2010-03-11 Repligen Corporation Compositions comprenant des dérivés d’acide 6-aminohexanoïque utilisées comme inhibiteurs de hdac
US8835648B2 (en) * 2009-06-11 2014-09-16 Siena Biotech S.P.A. Hedgehog pathway antagonists and therapeutic applications thereof
CN102574851A (zh) 2009-08-26 2012-07-11 武田药品工业株式会社 稠合杂环衍生物及其用途
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US9056865B2 (en) 2010-10-20 2015-06-16 Pfizer Inc. Pyridine-2-derivatives as smoothened receptor modulators
JP5452459B2 (ja) 2010-12-16 2014-03-26 株式会社Ｎｔｔドコモ ホーム基地局及びハンドオーバ方法
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US9540395B2 (en) 2011-02-28 2017-01-10 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US9051305B2 (en) 2011-03-08 2015-06-09 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
FR2980477B1 (fr) 2011-09-23 2013-10-18 Centre Nat Rech Scient Nouveaux composes modulateurs de la voie de signalisation des proteines hedgehog, leurs formes marquees, et applications
AU2012314943B9 (en) 2011-09-26 2017-06-08 Merck Patent Gmbh Benzyl piperidine compounds as lysophosphatidic acid (LPA) receptor antagonist
US20150133450A1 (en) 2012-06-20 2015-05-14 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
EP2922544B1 (fr) 2012-11-21 2018-08-01 Eutropics Pharmaceuticals, Inc. Méthodes et compositions utiles dans le traitement de maladies faisant appel à des protéines de la famille bcl-2 avec des dérivés de quinoléine
ES2680224T3 (es) 2013-03-15 2018-09-05 Biomarin Pharmaceutical Inc. Inhibidores de HDAC
US10435364B2 (en) 2013-04-17 2019-10-08 Albert Ludwigs Universität Freiburg Compounds for use as bromodomain inhibitors
WO2015017788A1 (fr) 2013-08-01 2015-02-05 Eutropics Pharmaceuticals, Inc. Méthode permettant de prédire la sensibilité d'un cancer
GB2519344A (en) * 2013-10-18 2015-04-22 Redx Pharma Ltd Compounds
JP6538044B2 (ja) 2013-10-30 2019-07-03 ユートロピクス ファーマシューティカルズ， インコーポレイテッド 化学療法感受性および化学毒性を判定する方法
KR102078444B1 (ko) * 2015-04-24 2020-02-17 화이자 인코포레이티드 1-((2r,4r)-2-(1h-벤조[d]이미다졸-2-일)-1-메틸피페리딘-4-일)-3-(4-시아노페닐)우레아 말레에이트의 결정질 형태
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
JP7792189B2 (ja) * 2019-03-29 2025-12-25 デクセリアルズ株式会社 接着剤組成物
EP4327881A3 (fr) 2020-01-28 2024-04-17 Assia Chemical Industries Ltd. Procédés de préparation de glassdegib et de son sel et formes à l'état solide de maléate de glassdegib et procédé de préparation de celui-ci
CN113248475B (zh) * 2020-02-11 2023-03-17 中国科学院上海药物研究所 一类杂环取代的苯并咪唑二聚体或其药学上可接受的盐、组合物及其用途
WO2021191278A1 (fr) 2020-03-26 2021-09-30 Lek Pharmaceuticals D.D. Forme dimaléate de 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-méthylpipéridine -4-yl)-3-(4-cyanophényl)urée
JP7327855B2 (ja) 2020-06-26 2023-08-16 ラクオリア創薬株式会社 レチノイドとがん治療薬との併用療法が有効ながん患者の選択方法およびレチノイドとがん治療薬との併用医薬
WO2023002362A1 (fr) 2021-07-22 2023-01-26 Pfizer Inc. Traitement d'une malignité hématologique

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040031782A (ko) 2001-07-27 2004-04-13 쿠리스 인코퍼레이션 헤지호그 신호전달 경로의 조절물질, 이를 함유하는조성물 및 이의 용도
MXPA04006599A (es) * 2001-12-04 2004-12-07 Actelion Pharmaceuticals Ltd 4-(piperidilo y pirrolidilo-aquilo-ureido)-quinolinas como antagonistas receptores de urotensina ii.
TW200304820A (en) 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
MXPA05003948A (es) 2002-10-17 2005-06-17 Amgen Inc Derivados de bencimidazol y su uso como ligandos de receptor vaniloide.
WO2005042495A1 (fr) 2003-10-21 2005-05-12 Imclone Systems Incorporated Composes de (benzimidazol-2-yl)-phenyl-phenyl-uree et procedes d'inhibition de l'activite de l'heparanase
NZ547109A (en) 2003-10-28 2010-03-26 Vertex Pharma Benzimidazoles useful as modulators of ion channels
JP2008519044A (ja) 2004-11-03 2008-06-05 キューリス，インコーポレーテッド ヘッジホッグ・シグナル伝達経路の伝達物質、調合物、及び、それに関連する使用
DE102005012875B4 (de) 2005-03-19 2006-11-16 Sanofi-Aventis Deutschland Gmbh Verwendung von Amino substituierten 8-N-Benzimidazolen
WO2006124780A2 (fr) * 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibiteurs de la b-raf kinase
WO2008064830A1 (fr) 2006-11-27 2008-06-05 Ucb Pharma, S.A. Dérivés bicycliques et hétérobicycliques, leurs procédés de fabrication et leurs utilisations pharmaceutiques
CA2672815A1 (fr) 2006-12-15 2008-06-26 Pfizer Products Inc. Derives du benzamidazole
NZ581889A (en) 2007-06-29 2011-05-27 Pfizer Benzimidazole derivatives
US20120094974A1 (en) 2008-06-17 2012-04-19 Wei Chen Smoothened receptor modulators
MX2011002060A (es) 2008-08-25 2011-04-05 Irm Llc Moduladores de la senda de hedgehog.

Also Published As

Publication number Publication date
US20090005416A1 (en) 2009-01-01
NZ581889A (en) 2011-05-27
ME00962B (fr) 2012-06-20
PT2170860T (pt) 2017-01-04
CR11150A (es) 2010-02-08
LTPA2020528I1 (lt) 2020-09-25
HN2008000974A (es) 2011-01-24
EP2170860B1 (fr) 2016-11-02
DK2170860T5 (en) 2017-03-20
CO6160232A2 (es) 2010-05-20
IL202420A0 (en) 2010-06-30
EP2170860B9 (fr) 2017-02-22
CN101687841B (zh) 2013-07-10
HUE030052T2 (hu) 2017-04-28
HRP20161562T1 (hr) 2016-12-30
JP4567099B2 (ja) 2010-10-20
IL202420A (en) 2014-05-28
CN101687841A (zh) 2010-03-31
NO2020027I1 (no) 2020-08-11
CU20090225A7 (es) 2012-02-15
RS55395B1 (sr) 2017-04-28
LTC2170860I2 (lt) 2022-03-10
DOP2009000278A (es) 2009-12-31
US20120157495A1 (en) 2012-06-21
RS55395B9 (sr) 2020-01-31
KR101143246B1 (ko) 2012-05-18
AR067346A1 (es) 2009-10-07
UY31164A1 (es) 2009-01-30
SI2170860T1 (sl) 2017-01-31
CA2690953A1 (fr) 2009-01-08
TWI371451B (en) 2012-09-01
PE20121010A1 (es) 2012-08-06
US8431597B2 (en) 2013-04-30
NL301057I1 (nl) 2020-07-22
GEP20125702B (en) 2012-12-10
HRP20161562T2 (hr) 2017-04-21
CU23847B1 (es) 2012-10-15
TW200911792A (en) 2009-03-16
AP2377A (en) 2012-03-07
CL2008001922A1 (es) 2009-01-02
WO2009004427A3 (fr) 2009-06-04
HUE030052T4 (en) 2017-06-28
MA31466B1 (fr) 2010-06-01
ES2609258T3 (es) 2017-04-19
AU2008272641B2 (en) 2013-08-29
WO2009004427A2 (fr) 2009-01-08
HK1139658A1 (en) 2010-09-24
EA200971104A1 (ru) 2010-06-30
JP2010531869A (ja) 2010-09-30
BRPI0813412B1 (pt) 2020-01-21
FR20C1038I1 (fr) 2020-10-02
NI200900219A (es) 2010-03-11
PE20090772A1 (es) 2009-06-24
EP2170860A2 (fr) 2010-04-07
PA8785401A1 (es) 2009-01-23
CY2020028I2 (el) 2020-11-25
AU2008272641A1 (en) 2009-01-08
HUS2000031I1 (hu) 2020-09-28
JP2010280693A (ja) 2010-12-16
GT200900328A (es) 2011-08-29
CY1118650T1 (el) 2017-07-12
LT2170860T (lt) 2017-01-10
ECSP099803A (es) 2010-01-29
DK2170860T3 (en) 2017-01-09
FR20C1038I2 (fr) 2021-08-13
PL2170860T3 (pl) 2017-05-31
CY2020028I1 (el) 2020-11-25
US8148401B2 (en) 2012-04-03
MY148636A (en) 2013-05-15
EA016888B1 (ru) 2012-08-30
KR20100028120A (ko) 2010-03-11
AP2009005089A0 (en) 2009-12-31
BRPI0813412B8 (pt) 2021-05-25
CA2690953C (fr) 2012-10-02
BRPI0813412A2 (pt) 2014-12-30
NL301057I2 (nl) 2020-09-10

Similar Documents

Publication Publication Date Title
TN2009000544A1 (fr) Derives de benzimidazole
TNSN08270A1 (fr) Dérivés pyrimidiques destinés à traiter une croissance cellulaire anormale
MA67365B1 (fr) Dérivés de benzisoxazole sulfonamide
TN2009000428A1 (fr) Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale
MA30403B1 (fr) Derives d'acides cycloalkylamines et leurs compositions pharmaceutiques
MA28747B1 (fr) Dérivés de pyridine
MA29926B1 (fr) Derives de pyrazine
TN2009000450A1 (fr) Derives de pyridine
MA30411B1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
MA31373B1 (fr) Composes amino-heterocycliques
TN2009000138A1 (fr) Biaryl-ether-urees
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
MA26727A1 (fr) Derives nouveaux de pyrimidine inhibiteurs de sorbitol deshydrogenase, leur procede de preparation et compositions pharmaceutiques les contenant
MA29909B1 (fr) Derives de pyridazine
MA27867A1 (fr) Nouveaux derives de 2h-pyridazine-3-one, compositions pharmaceutiques contenant ces derives et procede de preparation de l'ingredient actif.
TNSN97110A1 (fr) Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
BR0310106A (pt) Composto, processo para a produção de um composto, composição farmacêutica, uso do composto e método para o tratamento de um sujeito em sofrimento de uma condição ou doença patalógica
CY1110504T1 (el) Αναστολεις κινασης πρωτεϊνης
TN2014000115A1 (fr) Derives de pyrrolopyrimidines et de purines
EP2102225A4 (fr) Dérivés d'alpha-galactosylceramide, sels pharmaceutiquement acceptables de ceux-ci, procédé de préparation et composition pharmaceutique d'adjuvant immunologique contenant ces composés comme principe actif
TNSN05073A1 (fr) Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase
MA32009B1 (fr) Nouveaux derives de pyrazolo [3,4-d]pyrimidine en tant qu'agents anticancereux
MA24729A1 (fr) Macrolides nouveaux.
MA30959B1 (fr) Composes de pyrazole et de triazole substitues comme inhibiteurs de ksp